Related Experiment Video

Updated: Oct 10, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Prevention of respiratory syncytial virus infection with palivizumab

M Thomas1, A Bedford-Russell, M Sharland

  • 1Neonatal Unit, St. George's Hospital, London, UK.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|November 1, 2000
PubMed

Insights

Palivizumab reduces hospitalizations for premature infants with chronic lung disease (CLD) due to respiratory syncytial virus (RSV). However, its high cost limits use to specific high-risk infants, requiring further efficacy audits.

Area of Science:

  • Pediatric infectious diseases
  • Respiratory medicine
  • Pharmacoeconomics

Background:

  • Respiratory syncytial virus (RSV) is a common childhood infection, posing significant risks to premature infants with chronic lung disease (CLD).
  • Hospitalization rates for RSV in this vulnerable group have shown a declining trend over the last decade.
  • Palivizumab, a monoclonal antibody, offers prophylaxis against RSV infection.

Purpose of the Study:

  • To evaluate the efficacy and cost-effectiveness of palivizumab for preventing RSV-related hospitalizations in premature infants with CLD.
  • To identify specific subgroups of premature infants with CLD who may benefit most from palivizumab prophylaxis.

Main Methods:

  • Analysis of data from the IMpact trial, assessing the impact of palivizumab on RSV hospital admissions.
  • Cost-effectiveness analyses were conducted to determine the economic viability of palivizumab use.
  • Identification of specific patient criteria for palivizumab consideration.

Main Results:

  • The IMpact trial showed a 39% relative risk reduction in RSV hospital admissions with palivizumab use in premature infants with CLD.
  • Cost-effectiveness analyses indicate that palivizumab is not cost-effective for the majority of premature infants, including those with or without CLD.
  • Palivizumab use is primarily recommended for premature infants with CLD who are receiving home oxygen therapy during their first RSV season.

Conclusions:

  • Palivizumab demonstrates efficacy in reducing RSV hospitalizations for a select group of high-risk premature infants with CLD.
  • The high cost of palivizumab necessitates a targeted approach, limiting its use to infants with CLD on home oxygen.
  • Further post-licensing audits are crucial to validate the real-world efficacy of palivizumab in this specific high-risk population.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...